With NASH drug approval in the US on the horizon, energy has been high throughout the field. Nevertheless, we still face challenges – regulatory science must be aligned, and advocacy among stakeholders must be employed to help patients understand what to expect once we enter this new stage of NASH treatments. Learn about the latest in the field below:
AASLD Practice Guidance on the Clinical Assessment and Management of Nonalcoholic Fatty Liver Disease
Late last Friday, the American Association for the Study of Liver Disease (AASLD) released its much-anticipated guidance for managing NAFLD/NASH. This official practice guidance is intended to support providers with the information and pathway for serving liver patients with NAFLD/NASH.
This follows the guidelines released last year by the American Gastroenterological Association (AGA) and American Association of Clinical Endocrinology (AACE). With these practice guidelines now available, we have a clearer view of clinical pathways available for those at risk for NAFLD/NASH, determining risk for disease progression, and approaches for specialist referral
FDA Accepts Intercept’s New Drug Application for OCA For the Treatment of Pre-Cirrhotic Liver Fibrosis Due to NASH
Eying the first NASH approval, the FDA accepted Intercept Pharmaceutical’s New Drug Application (NDA) for obeticholic acid (OCA) to treat pre-cirrhotic liver fibrosis due to NASH. A team from the FDA will soon be reviewing the research on OCA’s safety and effectiveness. “This regulatory milestone brings us one step closer to reaching our goal of delivering the first available therapy for patients living with pre-cirrhotic fibrosis due to NASH – the most rapidly growing cause of liver transplantation in the U.S.,” says Jerry Durso, Intercept President and CEO. We are eager to see the next steps and opportunities this will bring not only for the liver health industry, but also for patients.
Surfing NASH Highlights Key Moments From Its Coverage of a Watershed Moment for Fatty Liver at NASH-TAG 2023
NASH-TAG 2023 provided attendees with a better understanding of current diagnostic procedures, prospects and challenges related to drug discovery and development for NASH and liver fibrosis. On an episode of Surfing the NASH Tsunami, Donna Cryer, GLI Founder and CEO, discusses her impressions from the conference regarding aligning regulatory science and expanding advocacy avenues. Mrs. Cryer emphasizes the importance of raising advocacy and energy among medical stakeholders and points out what drug and diagnostic companies can do to help physicians identify patients who need treatment after NASH drugs are approved.
Quantifying the Negative Impact of Fast-Food Consumption on Liver Steatosis Among United States Adults with Diabetes and Obesity
A recent analysis of data from the 2017-2018 National Health and Nutrition Examination Survey (NHANES) has quantified the impacts of fast-food consumption on liver health. Fast food consumption is associated with NAFLD, especially among obese or diabetic individuals. Those consuming fast food for one-fifth of their daily weight had significantly higher fat levels than those consuming the same amount of fast food without obesity or diabetes.
International NASH Day is on June 8, 2023!
Join us for International NASH Day, a public education campaign launched in June 2018 to raise visibility and urgency around fatty liver disease and its more advanced form, nonalcoholic steatohepatitis (NASH), which affects more than 115 million people around the world.
To learn more about the NASH Council or become a member, please visit https://globalliver.org/nash-council/ or reach out to NASH@globalliver.org